Liafensine

Liafensine
Clinical data
Routes of; administration	Oral
ATC code	None;
Legal status
Legal status	Development terminated;
Identifiers
	IUPAC name 6-[(4S)-2-Methyl-4-(2-naphthyl)-1,2,3,4-tetrahydro-7-isoquinolinyl]-3-pyridazinamine;
CAS Number	1198790-53-2;
PubChem CID	58212050;
ChemSpider	29271896;
UNII	R34ID086Z6;
KEGG	D10443;
CompTox Dashboard (EPA)	DTXSID60152610 ;
Chemical and physical data
Formula	C24H22N4
Molar mass	366.468 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1C[C@H](C2=C(C1)C=C(C=C2)C3=NN=C(C=C3)N)C4=CC5=CC=CC=C5C=C4;
	InChI InChI=1S/C24H22N4/c1-28-14-20-13-19(23-10-11-24(25)27-26-23)8-9-21(20)22(15-28)18-7-6-16-4-2-3-5-17(16)12-18/h2-13,22H,14-15H2,1H3,(H2,25,27)/t22-/m0/s1; Key:VCIBGDSRPUOBOG-QFIPXVFZSA-N;

Liafensine (BMS-820836) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) which was under development by Bristol-Myers Squibb for the treatment of major depressive disorder.^[1]^[2] Though it demonstrated comparable effectiveness to escitalopram and duloxetine in phase II clinical trials, development was paused in 2013 because liafensine failed to show superior effectiveness relative to these drugs, a decision that was made likely based on its increased capacity for side effects as well as potential for abuse.^[1] Another clinical trial of liafensine began in 2022.^[3]

References

^ ^a ^b "Digest". Progress in Neurology and Psychiatry. 17 (5): 41–43. 2013. doi:10.1002/pnp.305. ISSN 1367-7543. S2CID 222168896.
^ Bang-Andersen B, Bøgesø KP, Kehler J, Sánchez C (2017). "New Trends in Antidepressant Drug Research". In Ecker GF, Clausen RP, Sitte HH (eds.). Transporters as drug targets. Methods and Principles in Medicinal Chemistry. Weinheim, Germany: John Wiley & Sons. pp. 21–52 (22). doi:10.1002/9783527679430.ch2. ISBN 978-3-527-33384-4.
^ "CTG Labs - NCBI". clinicaltrials.gov. Retrieved 3 December 2023.